Mumps virus (MuV) is a highly contagious pathogen, and despite extensive vaccination campaigns, outbreaks continue to occur worldwide. The virus has a negative-sense, single-stranded RNA genome that is encapsidated by the nucleocapsid protein (N) to form the nucleocapsid (NC). NC serves as the template for both transcription and replication. In this paper we solved an 18-Å-resolution structure of the authentic MuV NC using cryo-electron microscopy. We also observed the effects of phosphoprotein (P) binding on the MuV NC structure. The N-terminal domain of P (P NTD ) has been shown to bind NC and appeared to induce uncoiling of the helical NC. Additionally, we solved a 25-Å-resolution structure of the authentic MuV NC bound with the C-terminal domain of P (P CTD ). The location of the encapsidated viral genomic RNA was defined by modeling crystal structures of homologous negative strand RNA virus Ns in NC. Both the N-terminal and C-terminal domains of MuV P bind NC to participate in access to the genomic RNA by the viral RNA-dependent-RNA polymerase. These results provide critical insights on the structurefunction of the MuV NC and the structural alterations that occur through its interactions with P.replication | paramyxovirus | mononegavirale P aramyxoviruses are enveloped nonsegmented negative-strand RNA viruses (NSV) belonging to the order Mononegavirales. Mononegavirales also includes the Bornaviridae, Filoviridae, and Rhabdoviridae families. The Paramyxoviridae family includes several important human pathogens such as measles virus (MeV), respiratory syncytial virus (RSV), and mumps virus (MuV). Although vaccines exist for some paramyxoviruses, they are not available for others, such as RSV. In addition, no effective antiviral treatments have been developed.The MuV genome encodes 9 proteins, three of which are required for replication of the MuV genome; the nucleocapsid protein (N), phosphoprotein (P), and the large protein (L). N, P, and L have orthologs in a number of NSV. Studies on the roles of N, P, and L in viral RNA synthesis have shown that each can individually and differentially affect the processes of mRNA transcription and genome replication (1-10).Throughout the virus replication cycle, the genome of NSV always exists in the nucleocapsid (NC), a unique protein-RNA complex in which the viral RNA [viral genomic RNA (vRNA) or complementary genomic RNA (cRNA)] is completely sequestered by the N protein. NC is used as the functional template for RNA synthesis by the viral RNA dependent RNA polymerase (vRdRp), which includes L and P. The L protein contains all of the enzymatic activities needed for viral RNA synthesis, such as the ability to cap and polyadenylate mRNA transcripts. P acts as a cofactor to home vRdRp onto the NC template for RNA synthesis. In addition, the P protein chaperones monomeric and RNA-free N to encapsidate newly synthesized viral genomes during replication. The encapsidation of RNA by N is concomitant with the replication process.How the sequestered vRNA is accessed by vRdRp ...

Mumps virus (MuV), a paramyxovirus containing a negative-sense nonsegmented RNA genome, is a human pathogen that causes an acute infection with symptoms ranging from parotitis to mild meningitis and severe encephalitis. Vaccination against mumps virus has been effective in reducing mumps cases. However, recently large outbreaks have occurred in vaccinated populations. There is no anti-MuV drug. Understanding replication of MuV may lead to novel antiviral strategies. MuV RNA-dependent RNA polymerase minimally consists of the phosphoprotein (P) and the large protein (L). The P protein is heavily phosphorylated. To investigate the roles of serine (S) and threonine (T) residues of P in viral RNA transcription and replication, P was subjected to mass spectrometry and mutational analysis. P, a 392-amino acid residue protein, has 64 S and T residues. We have found that mutating nine S/T residues significantly reduced and mutating residue T at 101 to A (T101A) significantly enhanced activity in a minigenome system. A recombinant virus containing the P-T101A mutation (rMuV-P-T101A) was recovered and analyzed. rMuV-P-T101A grew to higher titers and had increased protein expression at early time points. Together, these results suggest that phosphorylation of MuV-P-T101 plays a negative role in viral RNA synthesis. This is the first time that the P protein of a paramyxovirus has been systematically analyzed for S/T residues that are critical for viral RNA synthesis. IMPORTANCE Mumps virus (MuV) is a reemerging paramyxovirus that caused large outbreaks in the UnitedStates, where vaccination coverage is very high. There is no anti-MuV drug. In this work, we have systematically analyzed roles of Ser/Thr residues of MuV P in viral RNA synthesis. We have identified S/T residues of P critical for MuV RNA synthesis and phosphorylation sites that are important for viral RNA synthesis. This work leads to a better understanding of viral RNA synthesis as well as to potential novel strategies to control mumps. Mumps virus (MuV) is a human pathogen that causes acute parotitis and is highly neurotropic (1). Invasion of the central nervous system is evident in almost half of all clinical cases, with asceptic meningitis occurring in approximately 10% of cases and encephalitis in less than 1% (1). Even though the mumps vaccine has dramatically reduced disease incidence, large outbreaks have recently occurred in vaccinated populations (2, 3). Over 5,700 mumps cases were reported in a 2006 outbreak that originated at a university in Iowa and spread to 10 other states (2). A mumps outbreak occurred in New York and New Jersey in 2009 to 2010 where 88% of the patients had one dose of mumps vaccine and 75% of patients had two doses (3). There is no antiviral drug for MuV infection. Understanding functions of viral proteins will aid development of antiviral strategies. In this study, a strain of MuV from a recent outbreak in Iowa in 2006 (4), MuV Iowa/US/06 (referred to here as MuV), was used to examine the role of phosphorylation of the M...

Mycobacterium tuberculosis, the etiological agent of tuberculosis (TB), is an important human pathogen. Bacillus Calmette–Guérin (BCG), a live, attenuated variant of Mycobacterium bovis, is currently the only available TB vaccine despite its low efficacy against the infectious pulmonary form of the disease in adults. Thus, a more-effective TB vaccine is needed. Parainfluenza virus 5 (PIV5), a paramyxovirus, has several characteristics that make it an attractive vaccine vector. It is safe, inexpensive to produce, and has been previously shown to be efficacious as the backbone of vaccines for influenza, rabies, and respiratory syncytial virus. In this work, recombinant PIV5 expressing M. tuberculosis antigens 85A (PIV5-85A) and 85B (PIV5-85B) have been generated and their immunogenicity and protective efficacy evaluated in a mouse aerosol infection model. In a long-term protection study, a single dose of PIV5-85A was found to be most effective in reducing M. tuberculosis colony forming units (CFU) in lungs when compared to unvaccinated, whereas the BCG vaccinated animals had similar numbers of CFUs to unvaccinated animals. BCG-prime followed by a PIV5-85A or PIV5-85B boost produced better outcomes highlighted by close to three-log units lower lung CFUs compared to PBS. The results indicate that PIV5-based M. tuberculosis vaccines are promising candidates for further development.

The mumps virus (MuV) genome encodes a phosphoprotein (P) that is important for viral RNA synthesis. P forms the viral RNA-dependent RNA polymerase with the large protein (L). P also interacts with the viral nucleoprotein (NP) and self-associates to form a homotetramer. The P protein consists of three domains, the N-terminal domain (P N ), the oligomerization domain (P O ), and the C-terminal domain (P C ). While P N is known to relax the NP-bound RNA genome, the roles of P O and P C are not clear. In this study, we investigated the roles of P O and P C in viral RNA synthesis using mutational analysis and a minigenome system. We found that P N and P C functions can be trans-complemented. However, this complementation requires P O , indicating that P O is essential for P function. Using this trans-complementation system, we found that P forms parallel dimers (P N to P N and P C to P C ). Furthermore, we found that residues R231, K238, K253, and K260 in P O are critical for P's functions. We identified P C to be the domain that interacts with L. These results provide structure-function insights into the role of MuV P. IMPORTANCEMuV, a paramyxovirus, is an important human pathogen. The P protein of MuV is critical for viral RNA synthesis. In this work, we established a novel minigenome system that allows the domains of P to be complemented in trans. Using this system, we confirmed that MuV P forms parallel dimers. An understanding of viral RNA synthesis will allow the design of better vaccines and the development of antivirals. Mumps virus (MuV) is a human pathogen of the Rubulavirus genus of the Paramyxoviridae family that causes an acute infection with symptoms ranging from parotitis to mild meningitis and severe encephalitis (1). The nonsegmented, negativestranded RNA genome of MuV contains 15,384 nucleotides and encodes nine viral proteins (1). The viral RNA is encapsidated by the nucleoprotein (NP), and this helical nucleocapsid (RNP) functions as the template for viral RNA synthesis. Together, the large protein (L) and the phosphoprotein (P) make up the viral RNA-dependent RNA polymerase (vRdRp) (2). The enzymatic activities of the L protein involve the initiation, elongation, and termination of RNA synthesis, as well as mRNA capping (3). While P is not known to have intrinsic enzymatic activity, P is an essential cofactor of the polymerase. P oligomerizes by itself and forms complexes with L, NP, and RNP. It is thought that P docks the vRdRP to RNP (4).The P proteins of paramyxoviruses are modular and consist of N-terminal (P N ), oligomerization (P O ), and C-terminal (P C ) domains with flexible linkers between adjoining domains. The selfassociation of P is observed throughout negative-stranded RNA viruses (NSVs). The oligomerization domain of Sendai virus (SeV) P was the first to be crystallized, and those studies revealed a parallel coiled-coil tetramer (5, 6). The self-association of P is required for transcriptional activity, and the binding site for SeV L was found to neighbor the oligomerizat...

Although mumps vaccines have been used for several decades, protective immune correlates have not been defined. Recently, mumps outbreaks have occurred in vaccinated populations. To better understand the causes of the outbreaks and to develop means to control outbreaks in mumps vaccine immunized populations, defining protective immune correlates will be critical. Unfortunately, no small animal model for assessing mumps immunity exists. In this study, we evaluated use of type I interferon (IFN) alpha/beta receptor knockout mice (IFN-α/βR−/−) for such a model. We found these mice to be susceptible to mumps virus administered intranasally and intracranially. Passive transfer of purified IgG from immunized mice protected naïve mice from mumps virus infection, confirming the role of antibody in protection and demonstrating the potential for this model to evaluate mumps immunity.

and may be good candidates for vaccine development. In this study, we examined immunity induced by rMuV⌬SH and rMuV⌬V in mice. Furthermore, we generated recombinant mumps viruses lacking expression of both the V protein and the SH protein (rMuV⌬SH⌬V). Analysis of rMuV⌬SH⌬V indicated that it was stable in tissue culture cell lines. Importantly, rMuV⌬SH⌬V was immunogenic in mice, indicating that it is a promising candidate for mumps vaccine development. Mumps is a human infectious disease characterized by lateral or bilateral nonsuppurative swelling of the parotid glands. In severe cases, mumps can lead to orchitis in postpuberty male patients and damage to the central nervous system. In the prevaccine era, 90% of the population turned seropositive for mumps virus (MuV) by 14 to 15 years of age, reflecting its highly contagious nature. Mumps virus is neurotropic and was one of the most common causes of aseptic meningitis before the implementation of mass mumps vaccination programs.At present, the Jeryl Lynn (JL) vaccine is the most commonly used mumps vaccine, administered as lyophilized live virus with measles and rubella vaccine components. The JL vaccine strain originated from an infectious isolate from a mumps patient in 1963 (1). The virus was attenuated through continuous passages in embryonic hen eggs and chicken embryos/chicken embryo cell cultures (1). The JL vaccine was licensed in the United States in 1967 and has been used for over 40 years. This vaccine has been efficacious and safe overall (2-6). However, several large mumps outbreaks have occurred recently in the United States and worldwide in populations that have been vaccinated with the JL vaccine (7-10). Major mumps outbreaks in the United States include the 2006 multistate mumps outbreak, reporting 6,584 suspected cases originating from the state of Iowa (11, 12) and the 2009 -2010 New York and New Jersey mumps outbreaks with a total of 2,078 suspected cases reported in 2010 (13). Both of the outbreaks occurred among highly vaccinated populations, raising questions about the efficacy of the current vaccination program in the United States. One possible causality is the antigenic differences between the genotype A vaccine strain and the genotype G circulating wild-type mumps viruses.In this study, we seek to develop a mumps vaccine candidate through genetic modification of a clinically isolated mumps virus. Mumps virus is a member of the family Paramyxoviridae, subfamily Paramyxovirinae, and genus Rubulavirus (6,14). It is an enveloped virus enclosing a negative-sense, single-stranded, nonsegmented RNA genome of 15,384 nucleotides in length which encodes 9 viral proteins (15-17). Studies of the function of the Paramyxovirus SH protein reveal that it blocks tumor necrosis factor alpha (TNF-␣) induction, signaling, caspase activation, and NF-B nuclear translocation in transfected and virus-infected cells (18)(19)(20)(21)(22)(23). The V protein is an accessory protein translated from the authentic transcript of the V/P gene (24,25). Mumps V protein...

Mumps virus (MuV) is a paramyxovirus with a negative-sense nonsegmented RNA genome. The viral RNA genome is encapsidated by the nucleocapsid protein (NP) to form the ribonucleoprotein (RNP), which serves as a template for transcription and replication. In this study, we investigated the roles of phosphorylation sites of NP in MuV RNA synthesis. Using radioactive labeling, we first demonstrated that NP was phosphorylated in MuV-infected cells. Using both liquid chromatography-mass spectrometry (LC-MS) and in silico modeling, we identified nine putative phosphorylated residues within NP. We mutated these nine residues to alanine. Mutation of the serine residue at position 439 to alanine (S439A) was found to reduce the phosphorylation of NP in transfected cells by over 90%. The effects of these mutations on the MuV minigenome system were examined. The S439A mutant was found to have higher activity, four mutants had lower activity, and four mutants had similar activity compared to wild-type NP. MuV containing the S439A mutation had 90% reduced phosphorylation of NP and enhanced viral RNA synthesis and viral protein expression at early time points after infection, indicating that S439 is the major phosphorylation site of NP and its phosphorylation plays an important role in downregulating viral RNA synthesis. IMPORTANCEMumps virus (MuV), a paramyxovirus, is an important human pathogen that is reemerging in human populations. Nucleocapsid protein (NP) of MuV is essential for viral RNA synthesis. We have identified the major phosphorylation site of NP. We have found that phosphorylation of NP plays a critical role in regulating viral RNA synthesis. The work will lead to a better understanding of viral RNA synthesis and possible novel targets for antiviral drug development. Mumps virus (MuV) infects humans, causing acute infection with hallmark enlargement of the parotid gland (1). Before widespread vaccination in the late 1960s, mumps was the leading cause of aseptic meningitis and caused deafness in children (2). Although vaccination has greatly reduced the number of infections, large outbreaks have occurred recently in vaccinated populations. The largest recent outbreak in the United States originated at a university in Iowa in 2006, where over 5,000 cases were reported, compared to approximately 250 cases per year in the preceding years (3). In 2014, there were over 1,100 cases of mumps reported, mainly centered around universities (4). At least 90% of the individuals infected received the measles, mumps, and rubella (MMR) vaccine, and the majority of people received two doses (3). New strategies to control these outbreaks are needed. Understanding the roles of each MuV protein in virus replication and pathogenesis will aid development of countermeasures for MuV.Mumps virus (MuV) is a member of the family Paramyxoviridae in the genus Rubulavirus (1). It has a negative-sense, nonsegmented RNA genome of 15,384 nucleotides. The genome is comprised of seven transcriptional units that encode nine viral proteins i...

Mumps virus (MuV) causes acute infection in humans with characteristic swelling of the parotid gland. While vaccination has greatly reduced the incidence of MuV infection, there have been multiple large outbreaks of mumps virus (MuV) in highly vaccinated populations. The most common vaccine strain, Jeryl Lynn, belongs to genotype A, which is no longer a circulating genotype. We have developed two vaccine candidates that match the circulating genotypes in the United States (genotype G) and China (genotype F). We found that there was a significant decrease in the ability of the Jeryl Lynn vaccine to produce neutralizing antibody responses to non-matched viruses, when compared to either of our vaccine candidates. Our data suggests that an updated vaccine may allow for better immunity against the circulating MuV genotypes G and F.